Qureight Raises $20M Series B

Qureight, based in the United Kingdom, provides an end-to-end AI-powered imaging platform for clinical trials, with a specific focus on lung and heart disease. The company has announced the closing of a $20 million Series B funding round, bringing their total disclosed funding to over 27 million Euros.

Investors

The round was led by Molten Ventures, a prominent venture capital firm. Additional participating investors include Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension.

Qureight Use of Funds

Qureight intends to use the capital to accelerate the development of new AI disease models for lung and heart conditions and expand its imaging analytics platform. The funding will support the launch of new products in disease areas such as asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity. Furthermore, the company will build an AI imaging laboratory to house its 3D chest imaging Foundation Model to improve efficiency and reduce data requirements for model development.

About Qureight

Founded by Dr. Muhunthan Thillai, Qureight is a company that building an AI imaging laboratory to house Qureight’s 3D chest imaging Foundation Model. The company provides a regulatory-compliant, disease-agnostic platform that utilizes proprietary AI lung image biomarkers and data science products, such as synthetic control arms, to support biopharma partners in clinical research.

Funding Details

Company Website: https://qureight.com

Company: Qureight
Raised: $20M
Round: Series B
Funding Date: July 29, 2026
Lead Investor: Molten Ventures
Additional Investors: Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, Ascension
Company Website: https://qureight.com
Software Category: Healthtech
Source: https://tech.eu/2026/07/29/qureight-secures-20m-series-b-to-expand-ai-powered-imaging-platform-for-clinical-trials/